Full Press Release Details
USANA Health Sciences Reports Fourth Quarter and Fiscal Year 2023 Results
SALT LAKE CITY--(BUSINESS WIRE)--February 6, 2024--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and fiscal year ended December 30, 2023.
Key Financial Results & Guidance
Fourth quarter net sales were $221 million versus $228 million during Q4 2022 and $213 million during Q3 2023.
Fourth quarter diluted EPS was $0.87 as compared with $0.66 during Q4 2022.
Fiscal year 2023 net sales were $921 million as compared with $999 million during fiscal year 2022.
Fiscal year 2023 diluted EPS totaled $3.30 versus $3.59 during fiscal year 2022.
Company provides initial fiscal year 2024 net sales and diluted EPS guidance of $850 million to $920 million and $2.40 to $3.00, respectively.
| Q4 2023 Financial Performance | ||
| Consolidated Results | ||
| Net Sales | $221 million | -3% vs. Q4 2022 No meaningful FX impact +4% sequentially |
| Diluted EPS | $0.87 | +32% vs. Q4 2022 +47% sequentially |
| Active Customers | 483,000 | -1% vs. Q4 2022 +4% sequentially |
"USANA delivered solid fourth quarter operating results, which exceeded our expectations," said Jim Brown, President and Chief Executive Officer. "Our sales strengthened, in part, in response to a global incentive offering that was
particularly effective in our Greater China region where it helped generate double-digit sequential growth in Active Customer counts. This boost helped to offset the seasonal slowdown we typically experience during the final month of the
quarter and helped us finish the year strong."
| Fiscal Year 2023 Financial Performance | ||
| Consolidated Results | ||
| Net Sales | $921 million | -8% vs. prior year -5% constant currency vs. prior year -$28 million YOY FX impact, or -3% |
| Diluted EPS | $3.30 | -8% vs. prior year |
Mr. Brown continued, "Both net sales and diluted EPS for fiscal 2023 exceeded our guidance ranges. Although 2023 was a challenging year, we made meaningful progress on several strategic initiatives that will support future growth in customers
and net sales. For instance, we commenced operations in India, USANA's 25th global market, near the end of the fourth quarter and this market opening is a significant milestone for our company. Although we are just getting started in India and
expect a slow, steady and sustained growth trajectory, we are very optimistic about the long-term growth opportunity this important market provides."
| Q4 2023 Regional Results: | ||
| Asia Pacific Region | ||
| Net Sales | $177 million | -3% vs. Q4 2022 No meaningful FX impact +4% sequentially 80% of consolidated net sales |
| Active Customers | 383,000 | Flat vs. Q4 2022 +6% sequentially |
| Asia Pacific Sub-Regions | ||
| Greater China | ||
| Net Sales | $116 million | -2% vs. Q4 2022 -1% constant currency vs. Q4 2022 +9% sequentially |
| Active Customers | 255,000 | +5% vs. Q4 2022 +11% sequentially |
| North Asia | ||
| Net Sales | $22 million | -10% vs. Q4 2022 -12% constant currency vs. Q4 2022 -9% sequentially |
| Active Customers | 48,000 | -9% vs. Q4 2022 -2% sequentially |
| Southeast Asia Pacific | ||
| Net Sales | $39 million | -4% vs. Q4 2022 -3% constant currency vs. Q4 2022 Flat sequentially |
| Active Customers | 80,000 | -8% vs. Q4 2022 -4% sequentially |
| Americas and Europe Region | ||
| Net Sales | $44 million | -1% vs. Q4 2022 -3% constant currency vs. Q4 2022 +1% sequentially 20% of consolidated net sales |
| Active Customers | 100,000 | -6% vs. Q4 2022 -2% sequentially |
Balance Sheet and Share Repurchase Activity
The Company generated $26 million in operating cash flow during the fourth quarter and ended the year with $330 million in cash and cash equivalents. The Company did not repurchase any shares during the quarter. As of December 30, 2023, the
Company had approximately $71 million remaining under the current share repurchase authorization.
Fiscal Year 2024 Outlook
Mr. Brown continued, "Growth in Active Customers across all regions remains our top priority, and to this end we will continue to execute several key initiatives including: 1) Increased engagement with Associate leaders to further support
expansion of their businesses; 2) Enhanced, market-specific incentive offerings that reward growth; 3) Expansion of our presence in India; 4) Product innovation and development and; 5) Pursuit of additional acquisition opportunities.
The Company is introducing net sales and earnings per share outlook for fiscal year 2024, as detailed in the table below:
| Fiscal Year 2024 Outlook | |
| Range | |
| Consolidated Net Sales | $850 - $920 million |
| Diluted EPS | $2.40 - $3.00 |
"We are pleased with our fourth quarter results, which contributed to our strong finish to the year," said Doug Hekking, Chief Financial Officer. "That said, we encountered challenging economic conditions in many of our markets during 2023,
and we anticipate that 2024 will continue to be challenging."
Mr. Hekking added, "Our initial outlook for fiscal 2024 reflects year-over-year net sales performance between flat and down 7% on a constant currency basis. In making this YOY comparison, it is important to note that 2023 benefited from
approximately $25 million of incremental net sales in the first quarter, which is not expected to re-occur in the current year. We also anticipate that unfavorable currency exchange rates will have a modest negative impact on net sales in
"Our 2024 fiscal outlook assumes an operating margin of 8% to 9%, which reflects increased investments in India and our previously acquired businesses. We project an effective tax rate between 38% and 40% for the year and a diluted share
count of approximately 19.3 million."
Management Commentary Document and Conference Call
For further information on the USANA's operating results, please see the Management Commentary document, which has been posted on the Company's website (http://ir.usana.com) under the Investor Relations section. USANA's management team will
hold a conference call and webcast to discuss today's announcement with investors on Wednesday, February 7, 2024 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA's website at http://ir.usana.com. The call
will consist of brief opening remarks by the Company's management team, followed by a questions and answers session.
Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles ("GAAP"). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, "Financial Results") are
non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates ("FX") and help facilitate period-to-period comparisons of the Company's Financial Results that we believe provide investors an additional
perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period
and then comparing this amount to the prior-year period's Financial Results.
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong
Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can
be found at www.usana.com.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these
forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer
demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other
key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world,
including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology
systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and
operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health,
domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this release should be considered in conjunction with the risk factors, warnings, and
cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any
obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company's expectations, except as required by law.
| USANA Health Sciences, Inc. | ||||||||||||
| Consolidated Statements of Operations | ||||||||||||
| (In thousands, except per share data) | ||||||||||||
| (Unaudited) | ||||||||||||
| Quarter Ended | Twelve Months Ended | |||||||||||
| 30-Dec-23 | 31-Dec-22 | 30-Dec-23 | 31-Dec-22 | |||||||||
| Net sales | $ | 221,083 | $ | 227,960 | $ | 921,010 | $ | 998,601 | ||||
| Cost of sales | 42,319 | 46,430 | 176,693 | 193,890 | ||||||||
| Gross profit | 178,764 | 181,530 | 744,317 | 804,711 | ||||||||
| Operating expenses: | ||||||||||||
| Associate incentives | 95,881 | 97,879 | 394,257 | 434,793 | ||||||||
| Selling, general and administrative | 58,664 | 61,100 | 256,989 | 262,304 | ||||||||
| Earnings from operations | 24,219 | 22,551 | 93,071 | 107,614 | ||||||||
| Other income, net | 2,392 | 251 | 9,382 | 1,007 | ||||||||
| Earnings before income taxes | 26,611 | 22,802 | 102,453 | 108,621 | ||||||||
| Income taxes | 9,845 | 10,007 | 38,665 | 39,271 | ||||||||
| NET EARNINGS | $ | 16,766 | $ | 12,795 | $ | 63,788 | $ | 69,350 | ||||
| Earnings per share - diluted | $ | 0.87 | $ | 0.66 | $ | 3.30 | $ | 3.59 | ||||
| Weighted average shares outstanding - diluted | 19,253 | 19,263 | 19,345 | 19,310 |
| USANA Health Sciences, Inc. | ||||||
| Consolidated Balance Sheets | ||||||
| (In thousands) | ||||||
| (Unaudited) | ||||||
| As of | As of | |||||
| 30-Dec-23 | 31-Dec-22 | |||||
| ASSETS | ||||||
| Current Assets | ||||||
| Cash and cash equivalents | $ | 330,420 | $ | 288,420 | ||
| Inventories | 61,454 | 67,089 | ||||
| Prepaid expenses and other current assets | 25,872 | 28,873 | ||||
| Total current assets | 417,746 | 384,382 | ||||
| Property and equipment, net | 99,814 | 97,773 | ||||
| Goodwill | 17,102 | 17,368 | ||||
| Intangible assets, net | 29,919 | 32,432 | ||||
| Deferred tax assets | 13,284 | 9,799 | ||||
| Other assets* | 54,892 | 54,795 | ||||
| Total assets | $ | 632,757 | $ | 596,549 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| Current Liabilities | ||||||
| Accounts payable | $ | 10,070 | $ | 11,049 | ||
| Line of credit - short term | 786 | - | ||||
| Other current liabilities | 107,989 | 132,784 | ||||
| Total current liabilities | 118,845 | 143,833 | ||||
| Deferred tax liabilities | 4,552 | 4,071 | ||||
| Other long-term liabilities | 12,158 | 14,173 | ||||
| Stockholders' equity | 497,202 | 434,472 | ||||
| Total liabilities and stockholders' equity | $ | 632,757 | $ | 596,549 |
| USANA Health Sciences, Inc. | ||||||||||||||||||||||||||
| Sales by Region | ||||||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||
| Quarter Ended | ||||||||||||||||||||||||||
| December 30, 2023 | December 31, 2022 | Change from prior year | Currency impact on sales | % change excluding currency impact | ||||||||||||||||||||||
| Asia Pacific | ||||||||||||||||||||||||||
| Greater China | $ | 115,921 | 52.4 | % | $ | 118,290 | 51.9 | % | $ | (2,369 | ) | (2.0 | %) | $ | (1,352 | ) | (0.9 | %) | ||||||||
| Southeast Asia Pacific | 39,116 | 17.7 | % | 40,598 | 17.8 | % | (1,482 | ) | (3.7 | %) | (146 | ) | (3.3 | %) | ||||||||||||
| North Asia | 22,065 | 10.0 | % | 24,543 | 10.8 | % | (2,478 | ) | (10.1 | %) | 569 | (12.4 | %) | |||||||||||||
| Asia Pacific Total | 177,102 | 80.1 | % | 183,431 | 80.5 | % | (6,329 | ) | (3.5 | %) | (929 | ) | (2.9 | %) | ||||||||||||
| Americas and Europe | 43,981 | 19.9 | % | 44,529 | 19.5 | % | (548 | ) | (1.2 | %) | 678 | (2.8 | %) | |||||||||||||
| $ | 221,083 | 100.0 | % | $ | 227,960 | 100.0 | % | $ | (6,877 | ) | (3.0 | %) | $ | (251 | ) | (2.9 | %) |
| Active Associates by Region (1) | ||||||||||
| (Unaudited) | ||||||||||
| As of | ||||||||||
| December 30, 2023 | December 31, 2022 | |||||||||
| Asia Pacific | ||||||||||
| Greater China | 70,000 | 35.0 | % | 74,000 | 34.1 | % | ||||
| Southeast Asia Pacific | 52,000 | 26.0 | % | 62,000 | 28.6 | % | ||||
| North Asia | 32,000 | 16.0 | % | 34,000 | 15.6 | % | ||||
| Asia Pacific Total | 154,000 | 77.0 | % | 170,000 | 78.3 | % | ||||
| Americas and Europe | 46,000 | 23.0 | % | 47,000 | 21.7 | % | ||||
| 200,000 | 100.0 | % | 217,000 | 100.0 | % |
| Active Preferred Customers by Region (2) | ||||||||||
| (Unaudited) | ||||||||||
| As of | ||||||||||
| December 30, 2023 | December 31, 2022 | |||||||||
| Asia Pacific | ||||||||||
| Greater China | 185,000 | 65.4 | % | 170,000 | 62.3 | % | ||||
| Southeast Asia Pacific | 28,000 | 9.9 | % | 25,000 | 9.1 | % | ||||
| North Asia | 16,000 | 5.6 | % | 19,000 | 7.0 | % | ||||
| Asia Pacific Total | 229,000 | 80.9 | % | 214,000 | 78.4 | % | ||||
| Americas and Europe | 54,000 | 19.1 | % | 59,000 | 21.6 | % | ||||
| 283,000 | 100.0 | % | 273,000 | 100.0 | % |
| (1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale. |
| (2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market. |